SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

$AVNT is trending as the community discusses its recent price action and potential.  Traders are actively debating its volatility, entry points, and whether it can sustain its upward momentum.  Some believe its association with Coinbase and its position as a perp dex could drive future growth.

$BALLIN is the perfect meme for everyone showing up every single day.  To be BALLIN, you gotta B-All-In.  The meaning to B All In doesn't only apply to the funds you invest.  It's about dedication.   The countless hours of research.   The endless raiding and working for your bags.  Not knowing how to quit while everyone is telling you you're wrong.  It's about believing in something.  Keep $BALLIN

B All In

B All In ($BALLIN) is gaining attention, with community members highlighting its availability on Phantom Wallet and touting potential gains. The conversation centers around the idea of a "balling" lifestyle and the opportunity for early entry. However, some users are also expressing skepticism, labeling it a scam.

Vertiv Holdings Co. engages in the design, manufacture, and service of critical digital infrastructure technology for data centers, communication networks, and commercial and industrial environments. It also offers power management products, switchgear and busbar products, thermal management products, integrated rack systems, modular solutions, and management systems for monitoring and controlling digital infrastructure. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa (EMEA). The Americas segment offers products and services sold for applications within the data center, communication networks, and commercial and industrial markets in North America and Latin America. The Asia Pacific segment includes products and services sold for applications within the data center, communication networks, and commercial or industrial markets throughout Greater China, Australia and New Zealand, Southeast Asia, and India. The EMEA segment focuses on products and services sold for applications within the data center, communication networks, and commercial and industrial markets in Europe, Middle East, and Africa. The company was founded in 1946 and is headquartered in Columbus, OH.

Vertiv Holdings Co - Ordinary Shares - Class A

Vertiv Holdings Co

Vertiv is trending due to a combination of strong Q3 earnings, raised guidance, and positive analyst ratings, all driven by the increasing demand for AI infrastructure and data centers. The community is discussing the company's growth potential, strategic acquisitions, and its partnership with NVIDIA. Some investors express frustration with price action, while others remain bullish on the long-term prospects of Vertiv in the AI space.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

SMCI is trending due to a lowered Q1 revenue outlook, despite reaffirming strong full-year guidance and highlighting over $12 billion in new design wins for Q2 delivery. While some investors express frustration with management's forecasting, others view the dip as a buying opportunity, citing robust demand for AI solutions and confidence in long-term growth. Community discussions center on the significance of the delayed revenue and the potential for a rebound driven by strong Q2 performance.

STMicroelectronics NV is a global semiconductor company, which engages in the business of designing, developing, manufacturing, and marketing products used in a wide variety of applications for automotive, industrial, personal electronics and communications equipment, computers, and peripherals. It operates through the following segments: Automotive and Discrete Group (ADG), Analog, MEMS, and Sensors Group (AMS), Microcontrollers and Digital ICs Group (MDG), and Others. The ADG segment includes dedicated automotive integrated circuits and discrete and power transistor products. The AMS segment offers analog, smart power, MEMS sensors and actuators, and optical sensing solutions. The MDG segment focuses on general-purpose microcontrollers and microprocessors, connected security products, memories, and RF and communications products. The Others segment is involved in sales assembly services and other revenues. The company was founded in June 1987 and is headquartered in Plan-Les-Ouates, Switzerland.

ST Microelectronics - New York Shares

STMicroelectronics NV

STMicroelectronics is trending due to discussions around its Q3 earnings, with community members noting the disconnect between strong revenue and profit figures and a significant share price drop. Some speculate on potential causes for the price decline despite the company's solid performance in the European chip market and growing demand for its products. Investors are also sharing analyst ratings and discussing potential rebound opportunities.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending following its latest earnings report, which beat expectations and highlighted the company's focus on AI and foundry services. The community is discussing the potential for a significant rise, with some targeting $50 and beyond, driven by renewed confidence in Intel's growth prospects. Investors are also considering Intel's strategic importance and the impact of government support for domestic semiconductor manufacturing.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

The SPDR Dow Jones Industrial Average ETF ($DIA) is trending due to renewed US-China trade tensions following President Trump's threat of increased tariffs, sparking market volatility and a sell-off. Community discussions revolve around the potential economic impact and whether this is a buying opportunity or the start of a larger correction. Investors are also monitoring upcoming earnings reports and potential shifts in Federal Reserve policy in response to these developments.

Tecogen, Inc. engages in the production of commercial and industrial, natural-gas-fueled engine-driven, and combined heat and power (CHP) products. It operates through the Products, Services, and Energy Production segments. The Products segment designs, manufactures, and retails industrial and commercial cogeneration systems. The Services segment installs and maintains the cogeneration systems. The Energy Production segment sells energy in the form of electricity, heat, hot water, and cooling to customers under long-term sales agreements. The company was founded by George N. Hatsopoulos and John N. Hatsopoulos in 1987 and is headquartered in North Billerica, MA.

Tecogen Inc

Tecogen ($TGEN) is trending as investors focus on its potential role in providing energy solutions for AI data centers, especially given the increasing strain on electrical grids and the rising power demands of new chips. Community interest is centered on Tecogen's dual-fuel gas/electric systems and their potential partnership with Vertiv ($VRT) to offer efficient, resilient, and ESG-friendly solutions. Some believe a finalized deal or significant contract could dramatically reprice the stock, positioning it as a key player in distributed power and energy efficiency.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending as investors discuss the potential impact of AI developments and infrastructure investments, including a new data center project. Community members are weighing the stock's valuation and growth prospects ahead of upcoming earnings, with some anticipating a significant move. Discussions also involve technical analysis, potential partnerships, and the competitive landscape in the AI sector.

Modine Manufacturing Co. engages in the provision of thermal management products and solutions. It operates through the Climate Solutions and Performance Technologies business segments. The Climate Solutions segment provides climate-controlled solutions and components, heat transfer products, heating, ventilating, air conditioning and refrigeration products, and data center cooling solutions. The Performance Technologies segment designs and manufactures air- and liquid-cooled technology for vehicular, stationary power, and industrial applications. In addition, the Performance Technologies segment provides thermal solutions to zero-emission and hybrid commercial vehicle and automotive customers, and coating products and application services. The company was founded by Arthur B. Modine on June 23, 1916 and is headquartered in Racine, WI.

Modine Manufacturing Co.

Modine Manufacturing ($MOD) is trending as investors discuss its potential in air cooling solutions for AI data centers, drawing comparisons to Vertiv. Community members highlight catalysts like potential partnerships or funding announcements that could reprice the stock. Despite some concerns about weaker end-market demand and rising costs, MOD's acquisitions and turnaround strategy are also fueling positive sentiment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<a href="https://stocktwits.com/symbol/RGC">Regencell Bioscience Holdings Ltd</a>. (RGC), a Hong Kong-based nano-cap biotech firm, has emerged as one of the most explosive stocks of 2025, skyrocketing 14,486% year-to-date.The staggering rally has captivated retail traders and propelled the stock into the top trending ranks of healthcare chatter on Stocktwits.Over the past three months, message volume surrounding RGC has surged by 17,600% on Stocktwits, while its follower count has jumped 156%, reflecting some of the most intense engagement seen among small-cap health care stocks.Sentiment has mostly remained bullish over the same period, though cracks of doubt have&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rgc-stock-more-than-triples-this-year/ch7KEpeRbcl">emerged</a> as traders digest the stock’s rise despite no formal news or clear catalysts.<figure class="image"><img style="aspect-ratio:1322/1354;" src="https://news.stocktwits-cdn.com/RGC_YTD_chart_with_sentiment_meter_and_message_volume_as_of_May_29_png_6a489def8e.webp" alt="RGC YTD chart with sentiment meter and message volume as of May 29.png" width="1322" height="1354"><figcaption>RGC YTD chart with sentiment meter and message volume as of May 29. | source: Stocktwits</figcaption></figure>Many retail investors remain wary, with some warning of a looming correction."$RGC one of these days this dumps 99% in [a] single trading session," said one user.<stembedurl>https://stocktwits.com/ItSaulGoodMaan/message/616270456</stembedurl>"$RGC this went up 20,000 % in 3 months, if they didn’t just cure cancer, then this is a scam," said another.<stembedurl>https://stocktwits.com/Lard_ass_piggy/message/616269720</stembedurl>Hong Kong-based Regencell focuses on traditional Chinese medicine (TCM), developing formulas aimed at treating ADHD and autism spectrum disorder (ASD).Despite its mission, the company has yet to commercialize any treatments, apply for regulatory approvals, or secure patents.&nbsp;In its most recent annual filing in October, the firm disclosed net losses of $4.36 million for fiscal 2024 and noted it may “never be profitable.”Insider activity appears to be fueling much of the move. According to media reports, insiders control 81% of the float, limiting public liquidity and potentially amplifying volatility.As of June 30, 2024, Regencell reported $8 million in cash and short-term investments, which it believed was enough to cover expenses for at least the following 12 months. However, it said it will likely need “substantial additional financing” to continue operations.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Regencell Biotech Stock's Mind-Blowing 14,400% YTD Rally Draws Frenzied Retail Interest

Many retail investors remain wary, with some warning of a looming correction in the absence of formal news or clear catalysts.

Equity

Many retail investors remain wary, with some warning of a looming correction in the absence of formal news or clear catalysts.


Regencell Bioscience Holdings Ltd (3,500% Jump in Message Volume)Hong Kong-based Regencell focuses on traditional Chinese medicine for neurocognitive disorders, particularly ADHD and autism. Reports suggest its recent rally was fueled by insider buying, with insiders owning 81% of the company.&nbsp;However, a Stocktwits&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rgc-stock-more-than-triples-this-year/ch7KEpeRbcl">poll</a> indicates retail traders remain skeptical, with some flagging it as a potential pump-and-dump risk.&nbsp;The stock has surged 1,054% this year.GlucoTrack Inc. (2,800% Jump in Message Volume)GlucoTrack develops non-invasive glucose monitoring devices. It announced that safety and performance data from its first-in-human trial of a long-term continuous blood glucose monitoring (CBGM) system will be presented at the 2025 ATTD conference.&nbsp;CEO Paul V. Goode highlighted its potential for real-time glucose monitoring without on-body wearables, calling it a transformative step in diabetes management.&nbsp;GlucoTrack stock is down over 96% year-to-date (YTD).TC Biopharm (Holdings) Plc (1,300% Jump in Message Volume)TC Biopharm&nbsp;<a href="https://stocktwits.com/symbol/TCBP">received</a> a Nasdaq delisting notice due to its share price falling below $1. Trading will be suspended on Monday, with its American depository shares expected to move to OTC Markets.&nbsp;The company is also shifting to a contract development and manufacturing organization (CDMO) model, cutting about 50% of its workforce to reduce operational burn by 55%. This is projected to save $2.1 million in 2025 and $4.2 million annually.&nbsp;The stock is down over 95% YTD.AbbVie Inc. (700% Jump in Message Volume)Erste Group upgraded AbbVie to ‘Buy’ from ‘Hold’, according to The Fly, citing strong sales growth projections through 2029, supported by upcoming product launches. The research firm expects earnings per share (EPS) to rise significantly in 2025, ranging from $12.12 to $12.32.&nbsp;AbbVie recently agreed to acquire a next-gen obesity drug from Denmark-based Gubra A/S for up to $2.2 billion, boosting sentiment.&nbsp;The stock is up over 17.5% YTD.Actinium Pharmaceuticals Inc. (600% Jump in Message Volume)Actinium is launching trials for its drug Actimab-A in combination with Merck’s Keytruda and Bristol Myers Squibb’s Opdivo to treat solid tumors. The trials will include head-to-head studies comparing Actimab-A combinations to standalone treatments.&nbsp;The company also entered a research agreement with Memorial Sloan Kettering to expand Actimab-A’s applications.&nbsp;Actinium stock is up over 22% YTD.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A person examines financial data on a screen displaying a graph with upward and downward trends, using a pen to trace the line chart. | Representative Image: Getty Images

Regencell, GlucoTrack, TC Biopharm, AbbVie, Actinium: 5 Health Care Stocks That Lit Up Retail Discussions Last Week

Investors reacted to insider buying, clinical trial updates, and strategic business shifts that happened in the week ended March 21, 2025.

Regencell Bioscience Holdings Ltd. shares have been on a tear recently, more than tripling in value even before the first quarter of 2025 has ended. Retail traders, however, are not overly bullish about this stock.Hong Kong-based Regencell focuses on the research, development, and commercialization of traditional Chinese medicine, targeting neurocognitive disorders and degeneration, particularly attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD).According to several media&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://finance.yahoo.com/news/insiders-regencell-bioscience-holdings-limited-120457560.html">reports</a>, the recent rally has been driven mainly by buying from insiders, who own 81% of the company.The stock’s&nbsp;surge also comes amid a broader rally in Chinese stocks, driven by hopes of economic stimulus from Xi Jinping’s government.Koyfin data shows that only three institutional investors have a combined stake of a little over $156,000 in the company.A Stocktwits poll gauging retail sentiment on Regencell showed that 52% of nearly 1,000 respondents opted to stay away from the stock as it was "too risky for me," while 31% suggested they were buying it now.&nbsp;Another 12% said they were selling and taking profits, while 5% claimed to have "caught the move early."<figure class="image"><img style="aspect-ratio:1316/654;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/RGC_Stocktwits_poll_results_png_e989704d45.webp" alt="RGC Stocktwits poll results .png" width="1316" height="654"><figcaption>RGC Stocktwits poll results</figcaption></figure>Over the past three months, Regencell's following on Stocktwits has grown by 48% while message volume has soared by 30,000%.One bullish user claimed they bought Regencell stock when it was less than half its last close.<stembedurl>https://stocktwits.com/CryptoSenderX/message/607994621</stembedurl>However, a skeptic argued that RGC actually moved up "on no news. I'm shorting and waiting for the rug pull."<stembedurl>https://stocktwits.com/SmoothD/message/608057630</stembedurl>Regencell has not generated revenue or a profit ever since it went public on the Nasdaq in July 2021.&nbsp;It has a low float of about 802,000 shares, making it a highly volatile stock.One Stocktwits user expressed strong skepticism, saying, "This reeks of a scam so bad. Hong Kong biotech with 12 full-time employees. Chinese medicine ancient herbs for ADHD. This will collapse."<stembedurl>https://stocktwits.com/jimmieB/message/608370796</stembedurl>According to Koyfin, no analysts currently cover the stock on Wall Street. The stock ended Monday 46% higher and jumped another 42% in after-hours trading.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Regencell Bioscience Stock Is Up Over 260% This Year — Are Retail Traders Riding The Wave Or Watching From The Sidelines?

The Hong Kong-based company focuses on researching, developing, and commercializing traditional Chinese medicine, targeting neurocognitive disorders and degeneration.

12 titoli sanitari in movimento, sessione regolare del 22/03/2024

Titoli in rialzo
Il titolo IMAC Hldgs (NASDAQ:BACK) salito del 93,02% a 2,49 dollari durante la sessione regolare di venerd .
Il titolo Regencell Bioscience (NASDAQ:RGC) ha osservato un incremento...

12 acciones de salud en movimiento en la sesi n intrad a del 11/03/2024

Acciones al alza
Regencell Bioscience (NASDAQ:RGC) experimentaron un repunte del 130,88% para establecerse en los 10,39 d lares durante la sesi n del regular del lunes.
TC BioPharm (Holdings...

Regencell Bioscience Holdings Ltd trading resumes

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Regencell Bioscience Holdings Ltd trading halted, volatility trading pause

Regencell Bioscience Holdings Ltd. engages in the research, development, and commercialization of traditional Chinese medicine. It seeks the treatment of neurocognitive disorders and degeneration, specifically attention deficit hyperactivity disorder and autism spectrum disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Current Price	$16.02
Prev Close	$15.75
Open	$15.55
Dividend Yield	N/A
50-Day Moving Average	$15.14
Beta	-0.09
Avg. Volume	225,675.81
PE Ratio	-1,930.12

52-Week High	$83.60
52-Week Low	$0.0928
Market Capitalization	$7.92B
EPS (Annual)	N/A
Price to Book	1,179.68
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

RGC
Regencell Bioscience Holdings Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RGC News

RGCRegencell Bioscience Holdings Ltd